$0.74
3.88% yesterday
Nasdaq, Nov 15, 10:07 pm CET
ISIN
US38341P1021
Symbol
GOSS
Sector
Industry

Gossamer Bio, Inc. Stock price

$0.74
-0.23 23.54% 1M
-0.00 0.28% 6M
-0.17 18.89% YTD
-0.07 8.71% 1Y
-10.92 93.65% 3Y
-21.80 96.72% 5Y
-15.96 95.57% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.03 3.88%
ISIN
US38341P1021
Symbol
GOSS
Sector
Industry

Key metrics

Market capitalization $167.71m
Enterprise Value $44.31m
P/E (TTM) P/E ratio negative
EV/Sales (TTM) EV/Sales 0.42
P/S ratio (TTM) P/S ratio 1.59
P/B ratio (TTM) P/B ratio 3.10
Revenue (TTM) Revenue $105.32m
EBIT (operating result TTM) EBIT $-62.82m
Cash position $327.03m
EPS (TTM) EPS $-0.33
P/E forward negative
P/S forward 1.55
EV/Sales forward 0.46
Short interest 2.87%
Show more

Is Gossamer Bio, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Gossamer Bio, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Gossamer Bio, Inc. forecast:

7x Buy
70%
3x Hold
30%

Analyst Opinions

10 Analysts have issued a Gossamer Bio, Inc. forecast:

Buy
70%
Hold
30%

Financial data from Gossamer Bio, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
105 105
-
100%
- Direct Costs 4.07 4.07
10% 10%
4%
101 101
2,340% 2,340%
96%
- Selling and Administrative Expenses 29 29
18% 18%
27%
- Research and Development Expense 131 131
9% 9%
125%
-59 -59
68% 68%
-56%
- Depreciation and Amortization 4.07 4.07
10% 10%
4%
EBIT (Operating Income) EBIT -63 -63
67% 67%
-60%
Net Profit -72 -72
62% 62%
-68%

In millions USD.

Don't miss a Thing! We will send you all news about Gossamer Bio, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Gossamer Bio, Inc. Stock News

Neutral
Business Wire
4 days ago
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved...
Neutral
Business Wire
about one month ago
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved...
Positive
24/7 Wall Street
2 months ago
Penny stocks are an interesting category. While they have the potential to produce significant long-run gains, you should never bet money on these stocks that you can't afford to lose.
More Gossamer Bio, Inc. News

Company Profile

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi on October 25, 2015 and is headquartered in San Diego, CA.

Head office United States
CEO Faheem Hasnain
Employees 135
Founded 2015
Website www.gossamerbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today